Trevi Therapeutics (TRVI) Retained Earnings (2018 - 2026)
Trevi Therapeutics' quarterly Retained Earnings came in at -$190000.0 in Q1 2026, down 360.27% year-on-year from $73000.0 in Q1 2025, and down 228.38% quarter-over-quarter from $148000.0 in Q4 2025.
Trevi Therapeutics has reported Retained Earnings for 9 years, with the latest figure at -$190000.0 in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 360.27% year-over-year to -$190000.0; the trailing twelve-month figure through Mar 2026 stood at -$190000.0 (down 360.27% YoY), and the FY2025 full-year result was $148000.0, up 142.62% from the prior year.
- Retained Earnings for Q1 2026 stood at -$190000.0, down from $148000.0 in the prior quarter.
- The five-year high for Retained Earnings was $148000.0 in Q4 2025, with the low at -$262.4 million in Q2 2024.
- Average Retained Earnings over 5 years is -$79.7 million, with a median of -$190000.0 recorded in 2026.
- Peak annual rise in Retained Earnings reached 164.06% in 2024, while the deepest fall reached 284031.82% in 2024.
- Tracing TRVI's Retained Earnings over 5 years: stood at -$210.1 million in 2022, then declined by 13.84% to -$239.1 million in 2023, then surged by 100.03% to $61000.0 in 2024, then soared by 142.62% to $148000.0 in 2025, then tumbled by 228.38% to -$190000.0 in 2026.
- The last three Retained Earnings figures came in at -$190000.0 (Q1 2026), $148000.0 (Q4 2025), and $30000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | -190,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -190,000.00 |
| Dec 31, 2025 | 148,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 24,000.00 |
| Mar 31, 2025 | 73,000.00 |
| Dec 31, 2024 | 61,000.00 |
| Sep 30, 2024 | 139,000.00 |
| Jun 30, 2024 | -262.39 Mn |
| Mar 31, 2024 | -250.04 Mn |
| Dec 31, 2023 | -239.13 Mn |
| Sep 30, 2023 | -217,000.00 |
| Jun 30, 2023 | -248,000.00 |
| Mar 31, 2023 | -88,000.00 |
| Dec 31, 2022 | -210.07 Mn |
| Sep 30, 2022 | -204.56 Mn |
| Jun 30, 2022 | -135,000.00 |
| Mar 31, 2022 | -188.25 Mn |
| Dec 31, 2021 | -180.92 Mn |
| Sep 30, 2021 | -172.40 Mn |
| Jun 30, 2021 | -165.14 Mn |
| Mar 31, 2021 | -155.35 Mn |
| Dec 31, 2020 | -146.98 Mn |
| Sep 30, 2020 | -137.45 Mn |
| Jun 30, 2020 | -130.08 Mn |
| Mar 31, 2020 | -122.69 Mn |
| Dec 31, 2019 | -114.22 Mn |
| Sep 30, 2019 | -107.68 Mn |
| Jun 30, 2019 | -100.32 Mn |
| Mar 31, 2019 | -115.48 Mn |
| Dec 31, 2018 | -109.50 Mn |